Sentences with word «plasminogen»
Plasminogen is a protein that plays a crucial role in our body's blood clotting process. It is a precursor or an inactive form of the enzyme called plasmin, which helps dissolve blood clots. So, plasminogen is like a "starting material" that gets converted into plasmin to prevent unwanted clotting and maintain proper blood flow in our body. Full definition
N - terminal signal sequence of gp replaced by that of tissue plasminogen activator (tpa)- cleaved from
nibsc.org
Based on the gene expression profile, we demonstrated the significant changes of adipocytokine expression (up - regulation of adiponectin and down - regulation of plasminogen activator inhibitor - 1 and interleukin - 6).
In an elegant but still unfolding story of molecular detective work, researchers hunting for a cause of chronic kidney disease have homed in on a protein known as soluble urokinase plasminogen activator receptor (suPAR).
p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4 / cAMP / PKA pathway.
These results were not changed after adjusting for higher plasminogen activator inhibitor 1 and fibrinogen levels, which were found in women.
Its major target genes include proapoptotic genes Bax, Puma and Noxa, cell cycle regulator p21, and the senescence - inducing gene Plasminogen activator inhibitor 1 [5].
Kortlever RM, Higgins PJ and Bernards R. Plasminogen activator inhibitor - 1 is a critical downstream target of p53 in the induction of replicative senescence.
an enzyme produced by some strains of streptococcus that can liquefy blood clots by converting plasminogen to plasmin; used medicinally in some cases of myocardial infarction and pulmonary embolism
In a related editorial, Tiffany Cossey, M.D., and Nicole R. Gonzales, M.D., of The University of Texas Health Science Center at Houston, write: «Although sICH may be an uncommon occurrence, the known risk weighs heavily on the decision of clinicians to administer tPA [intravenous tissue plasminogen activator], as well as on the decisions of patients and families regarding treatment.
Everyone has urokinase plasminogen activator receptor (uPAR), a healthy molecule «tethered» in place to various types of cells.
Once there, they break apart into individual particles that stick to the clot, releasing a drug called tissue plasminogen activator (tPA) that dissolves it.
Researchers report that only 10 percent of frostbitten toes and fingers had to be amputated in patients who were given tissue plasminogen activator (tPA), an anti-clotting agent, in addition to standard frostbite treatment (rewarming, rehydrating and cleaning the wounded areas); in contrast, 41 percent of frostbitten digits had to be amputated in victims who received only conventional care.
Right now, the only widely available treatment for preventing brain damage from stroke is tissue plasminogen activator (tPA), which breaks up blood clots; it must be given within a few hours to be effective, and though it limits initial damage, it doesn't help the brain restore lost synapses or form new ones.
Researchers had already unearthed evidence that plasminogen activator inhibitor type 1 (PAI - 1), the protein encoded by the gene, influences aging - related illnesses.
Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) can improve outcomes for patients with ischemic stroke treated within 4 1/2 hours of the onset of symptoms.
While the clot - busting drug known as tPA (tissue plasminogen activator) had been the only medical therapy approved for treatment of acute stroke in the United States (U.S.), the projected U.K. cost savings of mechanical thrombectomy treatment as reported in the study could correlate to the U.S., making the treatment an even better option.
If given quickly enough, recombinant tissue plasminogen activator (rtPA) can in some cases dissolve the clot, restore blood flow and minimize damage.
Of the 698 who received the intravenous clot - busting drug tissue - plasminogen activator (IV tPA) alone, 27 percent were independent after treatment with no or minimal disability.
Plasminogen activator inhibitor - 1, or PAI - 1, is a naturally occurring protein within blood vessels that controls cell migration.
Intravenous tissue plasminogen activator (tPA; an enzyme that helps dissolve clots) reduces long - term disability when administered early to eligible patients with acute ischemic stroke.
The U.S. FDA has approved the clot - busting drug tissue plasminogen activator, or tPA, to be given within three hours of symptom onset, while the American Heart Association / American Stroke Association suggest it can be given up to 4.5 hours in some patients.
There is only one approved treatment — tissue plasminogen activator — but it is most effective when administered within 90 minutes after the onset of stroke.
Veress tested a clot - busting drug, tissue plasminogen activator (tPA), in rats exposed to normally lethal mustard doses — they all survived.
The patient received tissue Plasminogen Activator, a clot - dissolving drug, and improved clinically.
One of those proteins, called plasminogen - activator - inhibitor - 1 (PAI - 1) inhibits the production of another protein that breaks down blood clots; high levels of PAI - 1 mean the body doesn't break down clots as efficiently.
The only approved drug for stroke in the United States is an injectable medication called tissue plasminogen activator, or tPA.
The clot - busting drug tissue plasminogen activator (tPA) to treat ischemic stroke, should be given within 4.5 hours of symptom onset.
Tissue plasminogen activator (tPA) is a drug commonly used by surgeons to bust open blood clots in a patient's bloodstream, but it does have its limitations.
Thrombosis recanalization by paeoniflorin through the upregulation of urokinase - type plasminogen activator via the MAPK signaling pathway.
This protease activates hepatocyte growth factor (HGF) and urokinase plasminogen activator (uPA), two proteins thought to be involved in the growth and motility of cancer cells, particularly carcinomas, and in the vascularization of tumors.
To compare the safety and efficacy of tissue plasminogen activator (TPA) administered in controlled clinical trials to that of TPA prescribed in routine clinical practice.
He arrived too late to receive tissue plasminogen activator (tPA), the only treatment for ischemic strokes.
These standards relate to stroke rehabilitation & education, dysphagia screening, assessment of functional communication measures, use of antithrombotic agents, statin drugs, and tissue plasminogen activator, and management of transient ischemic attacks and migraine, and other related topics.
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.
He spent the early part of his career focused on commercial activities, including contributing to the successful launches of Activase ®, a recombinant tissue plasminogen activator (rtPA), and Nutropin ® human growth hormone (hGH) while working at Genentech.
Studies show that patients who receive endovascular rescue therapy after intravenous tissue plasminogen activator (IV tPA) have better outcomes than patients treated with medical therapy alone.
They include its effects on endothelial cell «differentiation» to yield tubular - like structures, endothelial and tumor cell proliferation, apoptosis, and migration, as well as its effects on extracellular matrix remodelling enzyme activities of matrix metalloproteinase - 2 (MMP - 2) and urokinase - type plasminogen activator (uPA).